Introduction
The incidence of Candida bloodstream infections (BSI) has doubled during the past two decades, becoming the fourth most frequent pathogen and now accounts for 8% of hospital acquired sepsis [1, 2] . Candida albicans causes 47 -60% of all candidemia [3] , although there has also been a documented increase in the proportion of infections caused by non-C. albicans Candida species [4] . Geographical variations are also apparent in the distribution of non-C . albicans Candida species implicated in BSI with C. glabrata predominating in the United States, C. parapsilosis in parts of Europe and Asia-Pacifi c and C. tropicalis in Latin America [3] . Recently, three distinct groups of C. parapsilosis (groups I, II, and III) were reclassifi ed as new adult), surgical wards and stem cell and kidney transplantation units. We defi ned a case of nosocomial candidemia as any patient having at least one positive blood culture yielding a Candida sp. and signs and symptoms of infection (i.e., fever, elevated WBC count, sepsis or septic shock) after at least 72 h of hospitalization. For patients with Ն 1 episode(s) of candidemia, the second episode was defi ned as a new case if it occurred Ն 4 weeks after the previous episode. Patients with candidemia caused by nonCandida yeasts were excluded from the analysis.
Blood cultures were processed in the Clinical Microbiology laboratory by an automated blood culture system (Bactec, BD, Paramus, NJ, USA). Yeasts were initially observed on Gram-stained preparations, subcultured on Sabouraud glucose agar and identifi ed by germ tube test, color on CHROMagar (CHROMagar, Paris, France), and carbohydrate assimilation reactions (ID 32 C, bioM é rieux, Marcy l ' Etoile, France). Identifi cation of species comprising the C. parapsilosis group was achieved using PCR. Amplifi cation of the SADH gene was performed by PCR with primers previously described by Tavanti et al . [5] . The SADH restriction profi le was used to discriminate C. parapsilosis sensu stricto , C. orthopsilosis and C. metapsilosis . Type strains AM 2001/0013 C. parapsilosis , J 96 0161 C. metapsilosis and J 98/226 C. orthopsilosis were used as controls.
Antifungal susceptibility testing was performed using disk diffusion (DD) testing of fl uconazole (25 μ g, Oxoid, UK) and voriconazole (1 μ g, Oxoid, UK) according to CLSI M44-A [9] . In vitro activity of amphotericin B was determined by Etest (AB Biodisk, Solna, Sweden) on RPMI-2% glucose agar. Candida parapsilosis ATCC 22019 was used for quality control of antifungal susceptibility tests. Strains with observed resistance were tested again using Sensititre YeastOne YO-5 panels (Trek Diagnostics, West Sussex, England ) according to the manufacturer ' s instructions.
The total antifungal usage was obtained from the hospital pharmacy database during the study period.
Results
Over the 4-year study period, 140,601 patients were admitted to our hospital and 6.7%, 34.9% and 57.3% of patients were monitored in the ICU, medical wards and surgery units, respectively. A total of 166 Candida strains demonstrated 157 candidemia episodes. Of these, 64 (38.6%) isolates were received for identifi cation during 2005 -2006 as compared to 102 (61.4%) during 2007 -2008 representing nearly a two-fold increase. Candida albicans was the most common species (34.3%). The most common non-C. albicans Candida sp. was C. parapsilosis (28.9%) followed by C. tropicalis (8.4%) ( Table 1 ). All 48 C. parapsilosis strains were identifi ed as C. parapsilosis sensu stricto .
In our study, distribution of Candida species among adults and pediatric patients were not markedly different. However, in the 2005 -2006 period, a relatively greater proportion of C. guilliermondii isolates were identifi ed among pediatric patients suggesting possible small outbreaks of candidemia.
Eleven isolates of Candida spp. were determined by CLSI DD testing as resistant to fl uconazole. After MIC determination using YeastOne panels, fl uconazole resistance was detected for three C. krusei strains. Two C. glabrata and one C. guilliermondii exhibited dose-dependent susceptibility. None of the isolates was found to be resistant to voriconazole including those that showed resistance to fl uconazole when tested by either DD or YeastOne panels. Two C. lusitaniae strains and one C. kefyr strain showed high amphotericin MIC (4 mg/l) ( Table 2 ). In terms of antifungals consumption in our hospital, while 
Discussion
It is generally acknowledged that epidemiological information available for one center or geographical region may not be applicable to others [10] . Candida albicans represents more than half of all isolates as shown by many European studies [11, 12] . Candida glabrata emerged second to C. albicans as a cause of BSI in virtually every survey based on US hospitals and some European hospitals [3, 13] . In our hospital, C. albicans was the prominent isolate while the most common non-C. albicans isolate was C. parapsilosis (28.9%) folllowed by C. tropicalis (8.4% ). A report from another part of our country (Western Turkey) showed C. albicans as the most common species with the second one being C. tropicalis (20.2%) followed by C. parapsilosis (12.5%) [14] . Our fi nding of C. parapsilosis as being the most common isolate of non-C. albicans Candida species may be related to insuffi cient implementation of infection control measures. Forrest et al . [15] showed that signifi cant correlations exist between increased caspofungin usage and an increased C. parapsilosis candidemia with reduction in C. tropicalis candidemia. According to our hospital pharmacy records, voriconazole usage increased 4.7 fold compared to caspofungin, which was a low preferred therapeutic agent during 2007 -2008 (data not shown).
Recently, the C. parapsilosis group has been renamed as three distinct species: C. parapsilosis sensu stricto , C. orthopsilosis and C. metapsilosis [5] . Since the two new species may inhabit important niches in certain patient populations, it is important to identify the distribution of these three species. Candida parapsilosis isolates in our study were C. parapsilosis sensu stricto . This is a similar fi nding to that of Silva et al . [16] who reported that all blood isolates were C. parapsilosis sensu stricto , while C. metapsilosis and C. orthopsilosis were only found in biological products other than blood although Lockhart et al . [17] interestingly identifi ed C. orthopsilosis and C. metapsilosis among bloodstream isolates at rates of 77% and 60%, respectively.
Our study showed that non-C. albicans Candida species isolated from BSI represent 65.7% of Candida isolates over the 4-year study period. Although fl uconazole and voriconazole were widely used in our hospital, there was no evidence of enhanced resistance. Large retrospective and guided epidemiological surveys using a common database are needed to monitor trends in incidence and changes in species distribution.
